Position in GRFS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$1,486
New position
Shares Held
210
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#147
of 164 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Silver Grove Financial Group, Inc. holds $3,091,763 across 16 Drug Manufacturers - General names. GRFS ranks #15 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
988 | $1,185,036 | |
| 2 | ABBV |
AbbVie Inc.
|
1,988 | $500,260 | |
| 3 | JNJ |
Johnson & Johnson
|
1,718 | $436,320 | |
| 4 | MRK |
Merck & Co., Inc.
|
1,425 | $183,112 | |
| 5 | AMGN |
Amgen Inc
|
420 | $152,090 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
2,491 | $143,531 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
921 | $116,359 | |
| 8 | NVO |
Novo Nordisk A S
|
1,900 | $91,086 |
All Filings in GRFS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,486 | 210 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||